A Cost-Effectiveness Analysis of Emicizumab Treatment in Non-Severe Haemophilia A Patients
By Staff Writer
April 17, 2024
Introduction: The Future of Haemophilia A Treatment
When it comes to rare blood diseases, the introduction of Emicizumab, a bispecific monoclonal antibody, has been a significant milestone in the treatment of haemophilia A. The drug, produced by Roche, mimics activated factor VIII (FVIII) and is administered via subcutaneous injection, offering a more convenient alternative to intravenous treatment options mostly used. However, the cost-effectiveness of Emicizumab in non-severe haemophilia A patients remains uncertain. This article aims to shed light on this issue.
The HAVEN 6 Trial: A Closer Look at Emicizumab’s Effectiveness
The HAVEN 6 trial demonstrated that patients with non-severe haemophilia A on prophylactic Emicizumab experienced a significant decrease in treated bleeding monthly probability. However, Emicizumab’s high cost, roughly $47,000 per month in the United States, raises questions about its cost-effectiveness.
Cost-effectiveness Analysis: Emicizumab vs Standard Recombinant FVIII
To evaluate the cost-effectiveness of Emicizumab compared to standard recombinant FVIII, a recent study developed a Markov model. The model evaluated the quality-adjusted life expectancy and costs for these patients, using a lifetime time horizon with a 1-month Markov cycle. The annual discount rate for cost and health outcomes is 3%, and the perspective is from the United States payer. The willingness-to-pay level (WTP) is set at $150,000 per quality-adjusted life year (QALY).
Findings: The Financial Implication of Emicizumab Treatment
The analysis revealed that Emicizumab prophylaxis resulted in 62% fewer treated bleed events over patients’ lifetimes than recombinant FVIII prophylaxis. However, the cost of Emicizumab prophylaxis accrued to $17,400,000, resulting in an incremental cost-effectiveness ratio (ICER) of 14.5 million USD/QALY, making it cost-ineffective compared to standard of care. The two secondary outcome threshold analyses showed that (1) a 100% reduction in chronic arthropathy prevalence (i.e., 0% chronic arthropathy) decreased the ICER to $1 160 000/QALY and (2) 1 mg of emicizumab must decrease by 35% to $64.60 to be cost-effective at $150 000/QALY.
Figure 1. State transition diagram and cost-effectiveness acceptability curve at a willingness-to-pay threshold of $150 000/QALY,
Global Perspective: Comparing Cost-Effectiveness Across Borders
Studies conducted in countries like Canada and reports from the Institute for Clinical and Economic Review suggest that Emicizumab prophylaxis can be cost-saving for patients with severe haemophilia A. However, this cost-saving benefit does not extend to patients with moderate or mild haemophilia A due to the lower prevalence of bleeding events and other related complications in this population. This discrepancy highlights the need for a more nuanced approach to pricing that takes into account the severity of the disease.
The Road Ahead: Pricing and Market Access
These findings underscore the need for careful consideration of indication-based pricing of novel therapies like Emicizumab. With the goal of value-based healthcare transformation in mind in the United States, indication-based pricing could improve patient outcomes at costs commensurate with clinical improvement.
Conclusion: Balancing Cost-Effectiveness and Therapeutic Innovation
In conclusion, the introduction of Emicizumab has undoubtedly shaken up the treatment landscape for haemophilia A, offering a more convenient and effective treatment option. However, the high cost of this novel therapy raises significant concerns about its cost-effectiveness, particularly for patients with non-severe haemophilia A. While Emicizumab prophylaxis has demonstrated significant clinical benefits in reducing bleeding events, its cost-effectiveness compared to standard recombinant FVIII remains unfavourable. Furthermore, the discrepancy in cost-effectiveness across different countries and patient populations underscores the need for a more nuanced approach to drug pricing, which considers the severity of the disease and the specific patient population. As the healthcare landscape continues to evolve towards a value-based model, it is crucial for stakeholders to balance the need for therapeutic innovation with cost-effectiveness. We must maintain a balance that makes new treatments like Emicizumab both affordable and accessible. This approach shouldn’t compromise the sustainability of healthcare systems. Future research should explore strategies to maximise the cost-effectiveness of these new therapies. One possible strategy is indication-based pricing. This way, we can ensure that we financially sustain the benefits of therapeutic innovation.
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
💡 Are we witnessing a paradigm shift in hemophilia treatment?
The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.
Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.
🌍 Are we witnessing a rise in HPV-related cancer in South Africa?
A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.
Dive into the findings and explore the implications for health systems and policies.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
